Celldex Therapeutics, Inc. (CLDX)
Market Cap | 2.44B |
Revenue (ttm) | 6.07M |
Net Income (ttm) | -144.88M |
Shares Out | 65.91M |
EPS (ttm) | -2.86 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 652,484 |
Open | 38.84 |
Previous Close | 38.99 |
Day's Range | 36.95 - 39.18 |
52-Week Range | 22.11 - 53.18 |
Beta | 1.47 |
Analysts | Buy |
Price Target | 66.00 (+78.33%) |
Earnings Date | Aug 6, 2024 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The c... [Read more]
Financial Performance
In 2023, CLDX's revenue was $6.88 million, an increase of 192.02% compared to the previous year's $2.36 million. Losses were -$141.43 million, 25.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $66.0, which is an increase of 78.33% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/f/s/conf16-2462429.jpg)
Celldex Therapeutics to Present at Jefferies Healthcare Conference
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on ...
![](https://cdn.snapi.dev/images/v1/c/4/press11-2457955.jpg)
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data...
![](https://cdn.snapi.dev/images/v1/a/n/press9-2431884.jpg)
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvoli...
![](https://cdn.snapi.dev/images/v1/8/s/press2-2413035.jpg)
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - En...
![](https://cdn.snapi.dev/images/v1/9/w/press4-2375565.jpg)
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolv...
![](https://cdn.snapi.dev/images/v1/c/c/press20-2315113.jpg)
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma ...
![](https://cdn.snapi.dev/images/v1/e/d/conf20-2308853.jpg)
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflam...
![](https://cdn.snapi.dev/images/v1/q/g/press18-2308769.jpg)
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public off...
![](https://cdn.snapi.dev/images/v1/9/m/press16-2302917.jpg)
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,...
![](https://cdn.snapi.dev/images/v1/7/y/press18-2299471.jpg)
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market condit...
![](https://cdn.snapi.dev/images/v1/8/z/press18-2293092.jpg)
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - En...
![](https://cdn.snapi.dev/images/v1/6/7/press13-2292352.jpg)
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid ons...
![](https://cdn.snapi.dev/images/v1/8/u/press5-2263015.jpg)
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Ann...
![](https://cdn.snapi.dev/images/v1/r/2/press2-2259671.jpg)
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzo...
![](https://cdn.snapi.dev/images/v1/j/d/conf9-2172928.jpg)
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx ...
![](https://cdn.snapi.dev/images/v1/7/g/press4-2146005.jpg)
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shar...
![](https://cdn.snapi.dev/images/v1/q/t/biotech17-2141373.jpg)
Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions
Celldex Therapeutics CLDX, +8.20% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammator...
![](https://cdn.snapi.dev/images/v1/s/r/press4-2141042.jpg)
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
-Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups- -Mean change from baseline to week 12 ...
![](https://cdn.snapi.dev/images/v1/l/g/press16-2140806.jpg)
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
- Response observed as early as week 1 and durable for up to 16 weeks - - Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications - - Phase ...
![](https://cdn.snapi.dev/images/v1/x/i/press12-2137462.jpg)
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch -
![](https://cdn.snapi.dev/images/v1/u/1/press1-2077484.jpg)
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodu...
![](https://cdn.snapi.dev/images/v1/z/r/conf6-2076129.jpg)
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conferenc...
![](https://cdn.snapi.dev/images/v1/8/a/press8-2012921.jpg)
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 - - First patient dosed in Phase 2 EoE study -
![](https://cdn.snapi.dev/images/v1/5/j/press13-1965740.jpg)
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolvo...
![](https://cdn.snapi.dev/images/v1/y/n/press14-1960334.jpg)
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvol...